Zysis Receives US Patent for Long Acting Oral Aripiprazole Once Weekly

Zysis, a private pharmaceutical company optimising therapies for disorders of the Central Nervous System, today announced that the United States Patent and Trademark Office has granted U.S. patent 8,575,172 covering its Phase II ready Long Acting Oral Aripiprazole Once Weekly (LAO Aripiprazole OW) product, a first-in-class antipsychotic therapy for orally dosed relapse prevention in patients suffering from Schizophrenia and Bipolar Disorders.

LAO Aripiprazole OW with medically supervised dosing is an alternative option to Long Acting Injectables (LAI) in the rapidly expanding market for prevention of psychotic relapse.



A pill in which you only have to take once a week, instead of once a day. This is really fascinating. Maybe in time, researchers might develop a medication that will last for months or even years in your system before you have to take the next dose.